Junevity, a metabolism and neurodegeneration-focused biotech, has raised $10 million, doubling its seed round to $20 million, CEO John Hoekman tells Axios Pro exclusively.
What's next: Junevity plans to approach investors about a Series A round in Q1 of 2026.
